


FLEXYTE™

...illuminating drug discovery

FLEXYTE™ assays harness the power and potential of fluorescence lifetime technology for screening and profiling applications.




- Assays available for a range of drug target classes
- Robust and reliable performance
- Homogenous and antibody free
- Minimises interference from problem compounds
- Applicable to fragment based screening

FLEXYTE™ assays brought to you by: **ALMAC**






NEW FLEXYTE™ Assays for Epigenetic Targets

- Assays developed for protein methyltransferases and deiminases
- FLEXYTE G9a methyltransferase and peptidylarginine deiminase 4 (PAD4) assays





FLEXYTE™ Protein Kinase Assays

- Peptide substrates labelled with 9-aminoacridine (9AA) dye
- Small molecule chelate (SMC) results in a reduction in fluorescence lifetime of only the phosphorylated peptide
- Approach validated for a panel of Ser / Thr and Tyr kinases
- Generic substrates configured for > 100 Ser / Thr kinases
- Z'-factors > 0.8
- Application to HTS demonstrated



FLEXYTE™ Protease Assays

- Cleavage of bespoke 9AA-labelled substrate liberates the dye from a lifetime modulator included at a specific site in the primary sequence
- Protease activity is monitored in real time by an increase in fluorescence lifetime
- Z'-factors > 0.8
- Bespoke labelled peptides can be configured for broad range of proteases
- Universal platform technology provides homogeneous, real-time monitoring of protease activity



For more information on how to transform your drug screening and profiling efforts visit:
www.flexyte-assays.com email: info@flexyte-assays.com Tel: +44 (0)28 3839 5794